Please login to the form below
Alnylam
This page shows the latest Alnylam news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Ionis sign $3.6bn deal for eplontersen
However, if approved, eplontersen will not have the ATTR market to itself and must compete with Pfizer’s Vyndaqel/Vyndamax (tafamidis) and Alnylam’s RNAi therapy Onpattro (patisiran).
Latest news
-
Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
Elsewhere in the therapy area is Alnylam’s Onpattro (patisiran), which received approval in hereditary ATTR amyloidosis (hATTR) in 2018.
-
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
Meanwhile, another non-clotting factor drug for haemophilia – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.
-
China backs use of Roche’s Actemra for coronavirus
In the meantime, Takeda and Alnylam have joined the companies working on drug treatments to tackle COVID-19 infections. ... Alnylam meanwhile says it is working with Vir Biotech on RNA interference drugs targeting ‘highly-conserved regions’ of
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam has claimed European Commission approval for its second RNA interface (RNAi) drug Givlaari for acute hepatic porphyria. ... Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
More from news
Approximately 19 fully matching, plus 46 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
2019 was a landmark year for gene-silencing specialist Alnylam and its chief executive John Maraganore. ... It’s all part of a plan that Maraganore thinks could catapult Alnylam into a top five position in the biopharma category within five years,
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Jerini. Commenting on the task ahead at Alnylam, she says: “It’s an incredibly exciting time for the company. ... Alnylam will face a similar process with Europe’s many national HTA organisations.
-
Brexit: the facts (and the alternative facts)
Two post-referendum announcements have boosted the UK Government. GSK announced a £275 million investment in its UK manufacturing sites and Alnylam, a US biotech worth $6.5bn, said it would
-
Managing value: Why early asset development and commercialisation are important
For example, Alnylam Pharmaceuticals, with its lead product in phase III, has a market capitalisation of $7.4bn, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation of
-
Deal Watch table for January 2014
Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products. ... 300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290.
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Editas Medicine adds to board of directors
Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins. Cambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors. ... He has extensive clinical development experience, a passion for scientific excellence, and
-
VC firm expands team, appoints Genzyme and Lilly veterans
The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies. ... Also joining Third Rock as venture partners are Daniel
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
EPG Health
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
-
How do you define a biotech company?
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
-
Managing value: Why early asset development and commercialization is important
For example, Alnylam Pharmaceuticals, with its lead product in Phase III, has a market capitalisation of $7.4 billion, despite having no marketed products; or Achillion Pharmaceuticals with a market capitalisation
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- EIT Health and Biogen announce winners of first ‘neurotechprize’
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program
- Scientists discover new approach to treat brain tumours
- UK trial of fourth vaccine dose shows increased protection against COVID-19
- Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- Recognising HIV Vaccine Awareness Day
- AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- How scientific storytelling can help Pharma cut through the noise
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Jardiance is first diabetes drug to improve CV outcomes
- Anthem PR appoints new managing director Rebecca Fergusson
- Christian Schade joins Aprea AB
- Assessing the value of interim analyses in clinical trials
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
- How scientific storytelling can help Pharma cut through the noise
- Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...
